Osimertinib (Tagrisso)
Targeted TherapyApproved for: NSCLCBiomarker: EGFR exon 19, exon 21 L858R Osimertinib (Tagrisso) approved Targeted Therapy for non small cell lung cancer (NSCLC) with the biomarker EGFR exon 19, exon 21 L858R. Osimertinib (Tagrisso) is an adjuvant therapy for NSCLC...